Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 8/20 | 0.39 |
| ▸ | JAK2 | O60674 | 3/20 | 0.38 |
| ▸ | JAK3 | P52333 | 3/20 | 0.38 |
| ▸ | SYK | P43405 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | USP1 | O94782 | 4/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13620506 | 0.89 | HSP90AA1 (0.40) | TLR7JAK2JAK3SYK | |
| SCHEMBL13620514 | 0.86 | BRD4 (0.43) | TLR7JAK2JAK3SYKADORA3 | |
| SCHEMBL12371672 | 0.86 | ADORA2A (0.43) | TLR7JAK2JAK3SYKADORA3 | |
| SCHEMBL13620235 | 0.86 | HSP90AA1 (0.41) | TLR7JAK2JAK3SYK | |
| SCHEMBL12371727 | 0.86 | PRKCQ (0.49) | TLR7JAK2JAK3ADORA3USP1 | |
| SCHEMBL13608357 | 0.86 | ADORA3 (0.43) | TLR7JAK2JAK3SYKADORA3 | |
| SCHEMBL12371703 | 0.85 | JAK2 (0.44) | TLR7JAK2JAK3ADORA3USP1 | |
| SCHEMBL13620291 | 0.85 | USP1 (0.41) | TLR7SYKADORA3USP1 | |
| SCHEMBL13620404 | 0.84 | USP1 (0.40) | TLR7JAK2JAK3ADORA3USP1 | |
| SCHEMBL12371675 | 0.84 | BRD4 (0.43) | TLR7JAK2JAK3ADORA3USP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PRKCE, PRKCZ, PRKCQ | TLR7 3960/4885JAK2 1072/4885JAK3 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.